Report scope. This 2026 Drug Asset Due Diligence Report evaluates Vididencel as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Vididencel is a Prophylactic vaccine associated with its disclosed target and a global highest development stage of Phase 2. The lead disclosed indication is Acute Myeloid Leukemia. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Vididencel
- Target: its disclosed target
- Lead indication: Acute Myeloid Leukemia
- Highest phase: Phase 2
- Matched trials: 4
- Matched result records: 9
- Matched asset deals: 3
Use PatSnap Life Sciences MCP servers to validate the Vididencel diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Vididencel, the MCP profile identifies its disclosed target as the primary target context and Acute Myeloid Leukemia as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Vididencel diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07651878 | Phase 1 | Recruiting | Not disclosed | Not disclosed |
| NCT04739527 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT03697707 | Phase 2 | Unknown status | Not disclosed | Not disclosed |
| NCT01373515 | Phase 1/2 | Completed | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Vididencel diligence evidence.
3. Clinical readouts: what is known
Vididencel, an active immunotherapy in high-grade serous ovarian carcinoma patients: Analysis of tumor-directed immune responses post-primary treatment.
Study: NCT04739527 (ASCO2026). Phase: Phase 1. Enrollment: 17. Published: 2026-05-29.
SD(with improved tumor-directed vididencel-induced immune responses) = 42.0 %
Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrate robust safety, relapse-free and overall survival benefit.
Study: ASH2025. Phase: Phase 2. Enrollment: 20. Published: 2025-12-06.
OS(4-year) = 66.5 % ( 42.5 - 82.3)
Mendus presents AML and solid tumor program data at CIMT
Study: NCT03697707 (ADVANCE II, Company_Website). Phase: Phase 2. Enrollment: Not disclosed. Published: 2025-05-16.
Long-term survival = 41.8 Month
LONG TERM SURVIVAL AND VACCINE-INDUCED IMMUNE RESPONSES ARE COMPARABLE BETWEEN NPM1 MUTATED VS NPM1 WILD TYPE AML PATIENTS AFTER IMMUNOTHERAPY WITH VIDIDENCEL
Study: NCT03697707 (ADVANCE-II, EHA2025). Phase: Phase 2. Enrollment: 20. Published: 2025-05-14.
OS = not yet reached Month | OS = not yet reached Month
Mendus and UMCG announce positive topline data from the ALISON trial with vididencel in ovarian cancer
Study: NCT04739527 (ALISON, NEWS). Phase: Phase 1. Enrollment: 17. Published: 2024-12-18.
SD(week 22) = 10 Pts
Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine
Study: NCT03697707 (ADVANCE-II, ASH2023). Phase: Phase 2. Enrollment: 20. Published: 2023-12-11.
SAE = none
Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001
Study: NCT01373515 (Literature). Phase: Phase 1. Enrollment: 12. Published: 2023-11-02.
mRFS = 420 Day (range, 90–1849) | -
Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment
Study: NCT03697707 (ADVANCE-II, GlobeNewswire). Phase: Phase 2. Enrollment: 20. Published: 2022-05-16.
MRD = 7 Pts
Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine
Study: NCT01373515 (ASH 12019 | ASH 22019). Phase: Phase 1. Enrollment: 12. Published: 2019-11-13.
mRFS = 420 Day
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Vididencel diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Vididencel against approved therapies and clinical competitors in Acute Myeloid Leukemia, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Vididencel diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2022-10-18 | Mendus AB has announced an agreement with Minaris Regenerative Medicine GmbH for the technology transfer and manufacturing of their lead development program DCP-001 | Active | Collaboration | Not disclosed |
| 2021-04-14 | Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai | Active | Collaboration | Not disclosed |
| 2019-09-10 | DCprime and UMCG collaborate on the development of DCP-001 for ovarian cancer. | Active | Collaboration | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Vididencel diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
